Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 6, 1997, Pages 643-651

  Bergstrom, Richard F ^a,b   Goldberg, Mark J ^a   Cerimele, Benito J ^a   Hatcher, Barbara L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUOXETINE; NORFLUOXETINE; TERFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ELECTROCARDIOGRAPHY; FIRST PASS EFFECT; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FLUOXETINE; HALF-LIFE; HEART; HEART RATE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; METABOLIC CLEARANCE RATE; SEROTONIN UPTAKE INHIBITORS; TERFENADINE;

EID: 0031417358     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90084-9     Document Type: Article

References (30)

1. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
2. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-6.
3. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1'hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 1994;11:921-4.
4. Goldberg MJ, Ring B, DeSante K, Cerimele B, Hatcher B, Sides G, et al. Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo. J Clin Pharmacol 1996;36:1154-60.
5. Robbins B, Chang CT, Cramer JA, Garreffa S, Hafkin B, Hunt TL, et al. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clin Pharmacol Ther 1996;59:275-83.
6. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR, Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264:2788-90.
7. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;259,12:1532-6.
8. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993; 266:964-71.
9. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-Demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275:592-7.
10. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995;275:1131-5.
11. Bergstrom RF, Beasley CM Jr, Levy NB, Blumenfield M, Lemberger L. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Int Clin Psychopharmacol 1993;8:261-6.
12. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
13. Marchiando RJ, Cook MD, Jue SG. Probable terfenadine-fluoxetine-associated cardiac toxicity. Ann Pharmacother 1995;29:937-8.
14. Swims MP. Potential terfenadine-fluoxetine interaction. Ann Pharmacother 1993;27:1404-5.
15. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-86.
16. Chen TM, Chan KY, Coutant JE, Okerholm RA. Determination of the metabolites of terfenadine in human urine by thermospray liquid chromatographymass spectrometry. J Pharm Biomed Anal 1991;9:929-33.
17. Garteiz DA, Hook RH, Walker BJ, Okerholm RA, Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimmittelforschung 1982;32: 1185-90.
18. Coutant F, Westmark P, Nardella P, Walter S, Okerholm R. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr Biomed App 1991;570:139-48.
19. Xu A, Linderholm K, Peng L, Hulse J. Development and validation of an LC-MS-MS method for the determination of terfenadine in human plasma. J Pharm Biomed Anal 1996;14:1675-80.
20. Nash JF, Bopp RJ, Carmichael RH, Farid ZK, Lemberger L. Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electroncapture detection. Clin Chem 1981;28:2100-2.
21. Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920;7:353-70.
22. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
23. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995;104:1-8.
24. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991;104:323-7.
25. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-6.
26. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
27. Strouse TB, Fairbanks LA, Skotzko CE, Fawzy FI. Fluoxetine and cyclosporine in organ transplantation. Psychosomatics 1996;37:23-30.
28. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
29. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58:492-7.
30. Smith SJ. Cardiovascular toxicity of antihistamines. Otolaryngol Head Neck Surg 1994;111:348-54.